Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philippe Couttet

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
The Journal of Pharmacology and Experimental Therapeutics|March 22, 2019
Colony-Stimulating Factor-1 Antibody Lacnotuzumab in a Phase 1 Healthy Volunteer Study and Mechanistic Investigation of Safety OutcomesFrancois Pognan, Philippe Couttet, Ivan Demin, et al.
Leukemia Research|December 7, 2010
Preclinical evaluation of potential nilotinib cardiotoxicityArmin Wolf, Philippe Couttet, Min Dong, et al.
Plos One|April 2, 2011
Phenobarbital mediates an epigenetic switch at the constitutive androstane receptor (CAR) target gene Cyp2b10 in the liver of B6C3F1 miceHarri Lempiäinen, Arne Müller, Sarah Brasa, et al.
Journal of Medicinal Chemistry|January 24, 2018
Discovery of the First Potent, Selective, and Orally Bioavailable Signal Peptide Peptidase-Like 2a (SPPL2a) Inhibitor Displaying Pronounced Immunomodulatory Effects In VivoJuraj Velcicky, Ursula Bodendorf, Pascal Rigollier, et al.
BMC Biotechnology|February 3, 2018
Two approaches for estimating the lower limit of quantitation (LLOQ) of microRNA levels assayed as exploratory biomarkers by RT-qPCRRussell D Wolfinger, Sudheer Beedanagari, Eric Boitier, et al.
Leukemia Research|February 4, 2010
Imatinib does not induce cardiotoxicity at clinically relevant concentrations in preclinical studiesArmin Wolf, Philippe Couttet, Min Dong, et al.
Plos One|August 4, 2012
Perturbation of microRNAs in rat heart during chronic doxorubicin treatmentCaterina Vacchi-Suzzi, Yasmina Bauer, Brian R Berridge, et al.
Science (New York, N.Y.)|April 28, 2007
Requirement of bic/microRNA-155 for normal immune functionAntony Rodriguez, Elena Vigorito, Simon Clare, et al.
Critical Reviews in Toxicology|May 26, 2021
Methodological considerations for measuring biofluid-based microRNA biomarkersBrian N Chorley, Elnaz Atabakhsh, Graeme Doran, et al.
Frontiers in Immunology|July 9, 2019
Imaging Mass Cytometry and Single-Cell Genomics Reveal Differential Depletion and Repletion of B-Cell Populations Following Ofatumumab Treatment in Cynomolgus MonkeysDiethilde Theil, Paul Smith, Catherine Huck, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
The Journal of Pharmacology and Experimental Therapeutics|March 22, 2019
Colony-Stimulating Factor-1 Antibody Lacnotuzumab in a Phase 1 Healthy Volunteer Study and Mechanistic Investigation of Safety OutcomesFrancois Pognan, Philippe Couttet, Ivan Demin, et al.
Leukemia Research|December 7, 2010
Preclinical evaluation of potential nilotinib cardiotoxicityArmin Wolf, Philippe Couttet, Min Dong, et al.
Plos One|April 2, 2011
Phenobarbital mediates an epigenetic switch at the constitutive androstane receptor (CAR) target gene Cyp2b10 in the liver of B6C3F1 miceHarri Lempiäinen, Arne Müller, Sarah Brasa, et al.
Journal of Medicinal Chemistry|January 24, 2018
Discovery of the First Potent, Selective, and Orally Bioavailable Signal Peptide Peptidase-Like 2a (SPPL2a) Inhibitor Displaying Pronounced Immunomodulatory Effects In VivoJuraj Velcicky, Ursula Bodendorf, Pascal Rigollier, et al.
BMC Biotechnology|February 3, 2018
Two approaches for estimating the lower limit of quantitation (LLOQ) of microRNA levels assayed as exploratory biomarkers by RT-qPCRRussell D Wolfinger, Sudheer Beedanagari, Eric Boitier, et al.
Leukemia Research|February 4, 2010
Imatinib does not induce cardiotoxicity at clinically relevant concentrations in preclinical studiesArmin Wolf, Philippe Couttet, Min Dong, et al.
Plos One|August 4, 2012
Perturbation of microRNAs in rat heart during chronic doxorubicin treatmentCaterina Vacchi-Suzzi, Yasmina Bauer, Brian R Berridge, et al.
Science (New York, N.Y.)|April 28, 2007
Requirement of bic/microRNA-155 for normal immune functionAntony Rodriguez, Elena Vigorito, Simon Clare, et al.
Critical Reviews in Toxicology|May 26, 2021
Methodological considerations for measuring biofluid-based microRNA biomarkersBrian N Chorley, Elnaz Atabakhsh, Graeme Doran, et al.
Frontiers in Immunology|July 9, 2019
Imaging Mass Cytometry and Single-Cell Genomics Reveal Differential Depletion and Repletion of B-Cell Populations Following Ofatumumab Treatment in Cynomolgus MonkeysDiethilde Theil, Paul Smith, Catherine Huck, et al.
Pageof 3